Dmitriy Zamarin MD, PhD

Dmitriy Zamarin MD, PhD, is a medical oncologist specializing in the care of women with gynecologic cancers, including cervical, ovarian, and endometrial cancers. He is Section Head of Gynecologic Medical Oncology and Co-Director of the Center of Excellence for Gynecologic Cancer at the Mount Sinai Tisch Cancer Center, an NCI-Designated Comprehensive Cancer Center. Dr. Zamarin is a member of the Icahn Genomics Institute and the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai.

Dr. Zamarin obtained his MD and PhD degrees from the Mount Sinai School of Medicine (now the Icahn School of Medicine at Mount Sinai). He completed residency in Internal Medicine at The Mount Sinai Hospital and fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center, where his research was focused on the mechanisms of response and resistance to cancer immunotherapy and development of novel immunotherapy treatment approaches. He spent a decade on the faculty at Memorial Sloan Kettering Cancer Center, where he served as Translational Research Director in Gynecologic Medical Oncology, before transitioning to his current role in September of 2023.

Dr. Zamarin has served as a principal investigator and a translational chair on multiple institutional and cooperative group clinical trials exploring novel immunotherapy combinations in gynecologic cancers and other solid tumors, and serves as the translational research co-chair on the NRG Oncology Cervical Cancer committee. His laboratory research is focused on understanding the mechanisms by which gynecologic cancers are recognized by the immune system and identifying biomarkers predictive of response and resistance to immunotherapy. His laboratory uses mouse models to explore the mechanisms of tumor-immune system interactions and to develop novel therapeutics, with particular focus on oncolytic viruses, vaccines, and targeted therapies. Dr. Zamarin has received awards and funding from multiple organizations including the Damon Runyon Foundation, the Ovarian Cancer Research Alliance, and the Department of Defense, as well as R01 grants from the National Cancer Institute. He is a member of the American Society for Clinical Investigation.